Purchase Order HHSN261201700263P

Award Date 8/11/17
Potential Completion Date 6/1/18
Potential Value $258K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a $243,100.71 firm fixed price purchase order to Childrens Hospital Medical Center (dba Children's Home Healthcare), a non-profit hospital located in Cincinnati, Ohio. The contract is for the production and biosafety testing of a current Good Manufacturing Practices (cGMP)-compliant transient gammaretroviral vector to be used in NCI clinical trials. The contract period of...
The U.S. National Heart Lung and Blood Institute (NHLBI) awarded a $598,672.91 cost-plus-fixed-fee task order contract to The Children's Hospital of Philadelphia (CHOP) for the Gene Therapy Resource Program (GTRP) AAV Vector Production Core Lab. This task order, which is part of a larger GTRP program, has a period of performance through May 31, 2017 and a current funding level of $325,007. The contract does not have a set-aside designation. CHOP, a leading pediatric hospital and research...
The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI) awarded a purchase order contract valued at one hundred twenty thousand six hundred dollars ($120,600) to Vector Biomed Inc. The contract is to obtain preclinical grade lentiviral vectors in support of NCI's Pediatric Oncology Branch investigational new drug enabling studies and demonstration of clinical-grade vector production feasibility. Services include receipt confirmation...
Children's Hospital Medical Center, doing business as Children's Home Healthcare, was awarded a $21,450 purchase order by the National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services. The firm fixed price contract is for laboratory testing services to support the NIH's research efforts. Performance will take place in Cincinnati, Ohio over a five-month period from August 1, 2023 through December 31, 2023. No subcontractors or...
This firm-fixed price purchase order contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Expression Manufacturing LLC, a for-profit limited liability company, to provide 250 ml of concentrated lentiviral vector and conduct stability testing. The contract, valued at $648,968.00, has an ultimate completion date of August 31, 2029. This sole-source procurement was originally...
This federal contract award to Childrens Hospital Medical Center, doing business as Children's Home Healthcare, is a $73,608.15 firm fixed-price delivery order under the National Institute of Allergy and Infectious Diseases (NIAID) Animal Models of Infectious Diseases 2010-2017 indefinite-delivery/indefinite-quantity (IDIQ) contract. The purpose of the task order is to conduct mouse model testing of a GSK GD-Alum/MPL vaccine. The contract has no set-aside designation. Childrens Hospital...
This federal contract award was issued by the National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Social & Scientific Systems, Inc., a subsidiary of DLH Holdings Corp. The $2,800,040 award is for Task Order 5 under the Gene Therapy Resource Program (GTRP) Clinical Coordinating Center, specifically for Task Area B related to clinical trials in fiscal year 2015. The contract is a cost-plus-fixed-fee type and does not have a set-aside...
This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) to Lentigen Technology, Inc., a for-profit organization, for the manufacture of a Good Manufacturing Practice (GMP) lot of a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting CD22. The contract, valued at $205,000.00, is for the production of this vector to support an ongoing clinical trial...
This is a $205,642 firm fixed-price purchase order awarded by the National Human Genome Research Institute (NHGRI), a component of the National Institutes of Health (NIH), to Children's Hospital, a non-profit pediatric academic health system in Washington, D.C. The contract is for the provision of rotations for medical genetics and genomic medicine residency and fellowship training programs. The contract has no set-aside designation, indicating Children's Hospital was competitively selected...
This is a federal contract award to Childrens Hospital Medical Center, a non-profit pediatric hospital and research center in Cincinnati, Ohio. The $1,334,309.94 contract is a delivery order under the NIAID Animal Models of Infectious Diseases 2010-2017 IDIQ contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The contract is for R&D - Medical: Biomedical (Basic Research) services and does not have a set-aside...

Childrens Hospital Medical Center, doing business as Children's Home Healthcare, was awarded a $258,310.00 firm-fixed-price purchase order by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health (NIH), to produce 20 liters of a clinical-grade, gamma-retroviral gene-therapy vector. This vector, to be generated using the transient transfection method, will encode a chimeric antigen receptor (CAR) recognizing a multiple myeloma antigen. The intended use is to transduce patient T cells, which will then be administered as a treatment for multiple myeloma in a clinical trial. The vector will be gibbon ape leukemia virus (GALV) pseudotyped and produced in 293T cells. The contract has a completion date of June 1, 2018. No set-aside designation was used.

Generated 3/23/24, 5:23 PM